TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Prospective, Placebo-controlled, Multi-center Study to Test the Efficacy of n-3 PUFA for the Maintenance of Normal Sinus Rhythm in Patients With Persistent Atrial Fibrillation
Brief Summary: To demonstrate that in patients with persistent atrial fibrillation who had recovered normal sinus rhythm and treated with the best recommended therapies, the addition of 1 gram / daily of n-3 PUFA is superior to the corresponding placebo for the maintenance of normal sinus rhythm at one year of follow up.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Omega 3 (n-3 PUFA) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega 3 (n-3 PUFA); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: AMR101; Type: EXPERIMENTAL; Interventions: Drug: AMR101, Drug: Statin therapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Statin therapy | Intervention Type: DRUG; Name: AMR101; Assigned to Arm(s): AMR101 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Statin therapy; Assigned to Arm(s): AMR101, Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: omega-3 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: omega-3, Behavioral: multi-domain intervention | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: multi-domain intervention, Drug: Placebo | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: omega-3; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: multi-domain intervention; Assigned to Arm(s): 2, 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3, 4
D: Arm Label: Aspirin + Omega-3 Ethyl Esters; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin, Drug: Omega-3 Ethyl Esters | Arm Label: Aspirin + Placebo Omega-3 Ethyl Esters; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin, Drug: Placebo Omega-3 Ethyl Esters | Arm Label: Placebo Aspirin + Omega-3 Ethyl Esters; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omega-3 Ethyl Esters, Drug: Placebo Aspirin | Arm Label: Placebo Aspirin + Placebo Omega-3 Ethyl Esters; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo Aspirin, Drug: Placebo Omega-3 Ethyl Esters | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Aspirin + Omega-3 Ethyl Esters, Aspirin + Placebo Omega-3 Ethyl Esters | Intervention Type: DRUG; Name: Omega-3 Ethyl Esters; Assigned to Arm(s): Aspirin + Omega-3 Ethyl Esters, Placebo Aspirin + Omega-3 Ethyl Esters | Intervention Type: DRUG; Name: Placebo Aspirin; Assigned to Arm(s): Placebo Aspirin + Omega-3 Ethyl Esters, Placebo Aspirin + Placebo Omega-3 Ethyl Esters | Intervention Type: DRUG; Name: Placebo Omega-3 Ethyl Esters; Assigned to Arm(s): Aspirin + Placebo Omega-3 Ethyl Esters, Placebo Aspirin + Placebo Omega-3 Ethyl Esters

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial on the Diaphragm Training With Threshold for Patient With Post-Cardiac Surgery Diaphragmatic Paralysis
Brief Summary: Diaphragm paralysis is a possible complication of cardiac surgery. The spontaneous recovery of the diaphragm mobility is slow and partial or absent in most cases. We hypothesize that a program of diaphragm muscle training by means of the Threshold variable resistance device could improve the rate of complete diaphragm mobility recovery in a shorter time period. Patient with post-cardiosurgical diaphragm paralysis will be random assigned to the specific training protocol or to a generic non-training physical activity.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Threshold | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Device: sham threshold | Intervention Type: DEVICE; Name: Threshold; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: sham threshold; Assigned to Arm(s): 2
B: Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise
C: Arm Label: Medtronic Transcatheter Aortic Valve Replacement Systems; Type: EXPERIMENTAL; Interventions: Device: Medtronic Transcatheter Aortic Valve Replacement Systems | Arm Label: Surgical Aortic Valve Replacement (SAVR); Type: ACTIVE_COMPARATOR; Interventions: Device: Surgical Aortic Valve Replacement (SAVR) | Intervention Type: DEVICE; Name: Medtronic Transcatheter Aortic Valve Replacement Systems; Assigned to Arm(s): Medtronic Transcatheter Aortic Valve Replacement Systems | Intervention Type: DEVICE; Name: Surgical Aortic Valve Replacement (SAVR); Assigned to Arm(s): Surgical Aortic Valve Replacement (SAVR)
D: Arm Label: CABG control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: PACO intervention for CABG patients; Type: EXPERIMENTAL; Interventions: Behavioral: PACO intervention for CABG patients | Arm Label: AVR control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: PACO intervention for AVR patients; Type: EXPERIMENTAL; Interventions: Behavioral: PACO intervention for AVR patients | Arm Label: MVR control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: PACO intervention for MVR patients; Type: EXPERIMENTAL; Interventions: Behavioral: PACO intervention for MVR patients | Intervention Type: BEHAVIORAL; Name: PACO intervention for CABG patients; Assigned to Arm(s): PACO intervention for CABG patients | Intervention Type: BEHAVIORAL; Name: PACO intervention for AVR patients; Assigned to Arm(s): PACO intervention for AVR patients | Intervention Type: BEHAVIORAL; Name: PACO intervention for MVR patients; Assigned to Arm(s): PACO intervention for MVR patients

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Should Intervention Through RADial Approach be Denied to Patients With Negative Allen's Test Results?
Brief Summary: The study will evaluate the feasibility and safety of radial approach in patients undergoing coronary catheterisation without any restrictions based on the results of Allen's test.


Options:
A: Arm Label: Arterial catheter; Type: OTHER; Interventions: Procedure: Laying a radial or femoral arterial catheter | Arm Label: Placement; Type: OTHER; Interventions: Procedure: Laying a radial or femoral arterial catheter | Intervention Type: PROCEDURE; Name: Laying a radial or femoral arterial catheter; Assigned to Arm(s): Arterial catheter, Placement
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: coronary catheterisation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: coronary catheterisation | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Procedure: coronary catheterisation | Intervention Type: PROCEDURE; Name: coronary catheterisation; Assigned to Arm(s): 1, 2, 3
C: Arm Label: Fluoroscopic + Ultrasound Guidance; Type: EXPERIMENTAL; Interventions: Procedure: Fluoroscopic + Ultrasound Guidance | Arm Label: Fluoroscopic Guidance Alone; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Fluoroscopic + Ultrasound Guidance; Assigned to Arm(s): Fluoroscopic + Ultrasound Guidance
D: Arm Label: direct palpation; Type: ACTIVE_COMPARATOR; Interventions: Device: Direct Palpation-guided Radial Artery Catheter insertion | Arm Label: Ultrasound; Type: ACTIVE_COMPARATOR; Interventions: Device: Ultrasound-guided Radial Artery Catheter Insertion | Intervention Type: DEVICE; Name: Ultrasound-guided Radial Artery Catheter Insertion; Assigned to Arm(s): Ultrasound | Intervention Type: DEVICE; Name: Direct Palpation-guided Radial Artery Catheter insertion; Assigned to Arm(s): direct palpation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: AFX01-14: A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Peginesatide for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated With Epoetin
Brief Summary: The purpose of this study was to evaluate the safety and efficacy of peginesatide in the maintenance treatment of anemia in participants on dialysis.


Options:
A: Arm Label: Peginesatide; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Epoetin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa or Epoetin beta | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide | Intervention Type: DRUG; Name: Epoetin alfa or Epoetin beta; Assigned to Arm(s): Epoetin
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: epoetin beta [NeoRecormon] | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): 1
C: Arm Label: RO0503821 (1x/2 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin (1x/1-2 Weeks); Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin (1x/1-2 Weeks) | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): RO0503821 (1x/2 Weeks)
D: Arm Label: C.E.R.A.; Type: ACTIVE_COMPARATOR; Interventions: Drug: comparison between darbepoetin alfa and C.E.R.A. and different administration intervals | Arm Label: Darbepoetin; Type: ACTIVE_COMPARATOR; Interventions: Drug: comparison between darbepoetin alfa and C.E.R.A. and different administration intervals | Intervention Type: DRUG; Name: comparison between darbepoetin alfa and C.E.R.A. and different administration intervals; Assigned to Arm(s): C.E.R.A., Darbepoetin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Oral Mucosal Decontamination With Chlorhexidine for Prevention of Ventilator Associated Pneumonia in Children - A Randomized Controlled Trial
Brief Summary: The purpose of this study is to determine if oral mucosal application of chlorhexidine gel will prevent the development of ventilator associated pneumonia in children.


Options:
A: Arm Label: Toothbrushing with a manual brush; Type: EXPERIMENTAL; Interventions: Device: Toothbrushing with a manual brush | Arm Label: No toothbrushing; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Toothbrushing with a manual brush; Assigned to Arm(s): Toothbrushing with a manual brush
B: Intervention Type: DRUG; Name: Chlorhexidine gluconate (drug) vs placebo; Assigned to Arm(s): N/A
C: Arm Label: Biotene OralBalance® gel Arm; Type: EXPERIMENTAL; Interventions: Drug: Biotene OralBalance® gel | Arm Label: Sterile Water Arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Sterile Water moisten cotton tipped applicator | Intervention Type: DRUG; Name: Biotene OralBalance® gel; Assigned to Arm(s): Biotene OralBalance® gel Arm | Intervention Type: OTHER; Name: Sterile Water moisten cotton tipped applicator; Assigned to Arm(s): Sterile Water Arm
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorhexidine gel | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo gel | Intervention Type: DRUG; Name: Chlorhexidine gel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo gel; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Oral Mucosal Decontamination With Chlorhexidine for Prevention of Ventilator Associated Pneumonia in Children - A Randomized Controlled Trial
Brief Summary: The purpose of this study is to determine if oral mucosal application of chlorhexidine gel will prevent the development of ventilator associated pneumonia in children.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorhexidine gel | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo gel | Intervention Type: DRUG; Name: Chlorhexidine gel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo gel; Assigned to Arm(s): 2
B: Arm Label: povidone iodine; Type: EXPERIMENTAL; Interventions: Drug: povidone iodine | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: povidone iodine; Assigned to Arm(s): povidone iodine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: 0.12% Chlorhexidie Digluconate; Type: EXPERIMENTAL; Interventions: Drug: 0.12% Chlorhexidine Digluconate | Arm Label: Toothbrushing; Type: PLACEBO_COMPARATOR; Interventions: Other: Toothbrushing | Intervention Type: DRUG; Name: 0.12% Chlorhexidine Digluconate; Assigned to Arm(s): 0.12% Chlorhexidie Digluconate | Intervention Type: OTHER; Name: Toothbrushing; Assigned to Arm(s): Toothbrushing
D: Arm Label: Biotene OralBalance® gel Arm; Type: EXPERIMENTAL; Interventions: Drug: Biotene OralBalance® gel | Arm Label: Sterile Water Arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Sterile Water moisten cotton tipped applicator | Intervention Type: DRUG; Name: Biotene OralBalance® gel; Assigned to Arm(s): Biotene OralBalance® gel Arm | Intervention Type: OTHER; Name: Sterile Water moisten cotton tipped applicator; Assigned to Arm(s): Sterile Water Arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: AFX01-12: A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Peginesatide for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated With Epoetin Alfa
Brief Summary: The purpose of the study was to evaluate the safety and efficacy of peginesatide in the maintenance treatment of anemia in participants on dialysis.


Options:
A: Arm Label: Peginesatide; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Epoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin Alfa | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide | Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): Epoetin alfa
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: epoetin beta [NeoRecormon] | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): 1
C: Arm Label: Early Epoetin Beta Therapy; Type: EXPERIMENTAL; Interventions: Drug: epoetin beta [NeoRecormon] | Arm Label: Late Epoetin Beta Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: epoetin beta [NeoRecormon] | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Early Epoetin Beta Therapy | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Late Epoetin Beta Therapy
D: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): Active

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Operations and Pelvic Muscle Training in the Management of Apical Support Loss: The OPTIMAL Trial: A Randomized Trial of Sacrospinous Ligament Fixation (SSLF) Versus Uterosacral Ligament Suspension (ULS) With and Without Perioperative Behavioral Therapy/Pelvic Muscle Training
Brief Summary: Pelvic organ prolapse is common among women with a prevalence that has been estimated to be as high as 30%. Pelvic organ prolapse often involves a combination of support defects involving the anterior, posterior and/or apical vaginal segments. While the anterior vaginal wall is the segment most likely to demonstrate recurrent prolapse after reconstructive surgery, reoperations are highest among those who require apical suspension procedures with or without repair of other vaginal segments (12%-33%). Despite the substantial health impact, there is a paucity of high quality evidence to support different practices in the management of prolapse, particularly surgery. Thus, the objectives of the Operations and Pelvic Muscle Training in the Management of Apical Support Loss (OPTIMAL) Trial are:

1. to compare sacrospinous ligament fixation (SSLF) to uterosacral vaginal vault ligament suspension (ULS); and
2. to assess the role of perioperative behavioral therapy/pelvic muscle training (PMT) in women undergoing vaginal surgery for apical or uterine prolapse and stress urinary incontinence.


Options:
A: Arm Label: SSLF and PMT; Type: EXPERIMENTAL; Interventions: Procedure: SSLF, Behavioral: PMT | Arm Label: ULS and PMT; Type: EXPERIMENTAL; Interventions: Procedure: ULS, Behavioral: PMT | Arm Label: SSLF without PMT; Type: EXPERIMENTAL; Interventions: Procedure: SSLF | Arm Label: ULS without PMT; Type: EXPERIMENTAL; Interventions: Procedure: ULS | Intervention Type: PROCEDURE; Name: SSLF; Assigned to Arm(s): SSLF and PMT, SSLF without PMT | Intervention Type: PROCEDURE; Name: ULS; Assigned to Arm(s): ULS and PMT, ULS without PMT | Intervention Type: BEHAVIORAL; Name: PMT; Assigned to Arm(s): SSLF and PMT, ULS and PMT
B: Arm Label: Single-port sacrocolpopexy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Single-port sacrocolpopexy | Arm Label: Multi-port sacrocolpopexy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Multi-port sacrocolpopexy | Intervention Type: PROCEDURE; Name: Single-port sacrocolpopexy; Assigned to Arm(s): Single-port sacrocolpopexy | Intervention Type: PROCEDURE; Name: Multi-port sacrocolpopexy; Assigned to Arm(s): Multi-port sacrocolpopexy
C: Intervention Type: PROCEDURE; Name: sacral colpopexy; Assigned to Arm(s): N/A
D: Arm Label: Anchor; Type: EXPERIMENTAL; Interventions: Other: Anchor | Arm Label: Suture; Type: ACTIVE_COMPARATOR; Interventions: Other: Suture | Intervention Type: OTHER; Name: Anchor; Assigned to Arm(s): Anchor | Intervention Type: OTHER; Name: Suture; Assigned to Arm(s): Suture

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Operations and Pelvic Muscle Training in the Management of Apical Support Loss: The OPTIMAL Trial: A Randomized Trial of Sacrospinous Ligament Fixation (SSLF) Versus Uterosacral Ligament Suspension (ULS) With and Without Perioperative Behavioral Therapy/Pelvic Muscle Training
Brief Summary: Pelvic organ prolapse is common among women with a prevalence that has been estimated to be as high as 30%. Pelvic organ prolapse often involves a combination of support defects involving the anterior, posterior and/or apical vaginal segments. While the anterior vaginal wall is the segment most likely to demonstrate recurrent prolapse after reconstructive surgery, reoperations are highest among those who require apical suspension procedures with or without repair of other vaginal segments (12%-33%). Despite the substantial health impact, there is a paucity of high quality evidence to support different practices in the management of prolapse, particularly surgery. Thus, the objectives of the Operations and Pelvic Muscle Training in the Management of Apical Support Loss (OPTIMAL) Trial are:

1. to compare sacrospinous ligament fixation (SSLF) to uterosacral vaginal vault ligament suspension (ULS); and
2. to assess the role of perioperative behavioral therapy/pelvic muscle training (PMT) in women undergoing vaginal surgery for apical or uterine prolapse and stress urinary incontinence.


Options:
A: Arm Label: Abdominal Sacral Colpopexy with no Burch colposuspension; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Abdominal Sacral Colpopexy with Burch Colposuspension; Type: EXPERIMENTAL; Interventions: Procedure: Burch urethropexy at time of sacrocolpopexy | Intervention Type: PROCEDURE; Name: Burch urethropexy at time of sacrocolpopexy; Assigned to Arm(s): Abdominal Sacral Colpopexy with Burch Colposuspension
B: Arm Label: Prolift mesh; Type: ACTIVE_COMPARATOR; Interventions: Device: synthetic monofilament polypropylene mesh | Arm Label: Prolapse repair without mesh; Type: ACTIVE_COMPARATOR; Interventions: Device: synthetic monofilament polypropylene mesh | Intervention Type: DEVICE; Name: synthetic monofilament polypropylene mesh; Assigned to Arm(s): Prolapse repair without mesh, Prolift mesh
C: Intervention Type: PROCEDURE; Name: sacral colpopexy; Assigned to Arm(s): N/A
D: Arm Label: SSLF and PMT; Type: EXPERIMENTAL; Interventions: Procedure: SSLF, Behavioral: PMT | Arm Label: ULS and PMT; Type: EXPERIMENTAL; Interventions: Procedure: ULS, Behavioral: PMT | Arm Label: SSLF without PMT; Type: EXPERIMENTAL; Interventions: Procedure: SSLF | Arm Label: ULS without PMT; Type: EXPERIMENTAL; Interventions: Procedure: ULS | Intervention Type: PROCEDURE; Name: SSLF; Assigned to Arm(s): SSLF and PMT, SSLF without PMT | Intervention Type: PROCEDURE; Name: ULS; Assigned to Arm(s): ULS and PMT, ULS without PMT | Intervention Type: BEHAVIORAL; Name: PMT; Assigned to Arm(s): SSLF and PMT, ULS and PMT

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Pioglitazone on Insulin Resistance, Insulin Secretion and Atherosclerosis in Renal Allograft Recipients Without History of Diabetes
Brief Summary: The aim of this study was to evaluate the effect of pioglitazone treatment on insulin secretion, insulin resistance, and progression of atherosclerosis in renal allograft recipients without preoperative history of diabetes.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Pioglitazone | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): 1
B: Arm Label: Canagliflozin 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Canagliflozin; Assigned to Arm(s): Canagliflozin 100 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1.5 mg Dulaglutide; Type: EXPERIMENTAL; Interventions: Drug: Dulaglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dulaglutide; Assigned to Arm(s): 1.5 mg Dulaglutide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Semaglutide 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: semaglutide | Arm Label: Semaglutide 1.0 mg; Type: EXPERIMENTAL; Interventions: Drug: semaglutide | Arm Label: Semaglutide placebo 0.5 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Semaglutide placebo 1.0 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: semaglutide; Assigned to Arm(s): Semaglutide 0.5 mg | Intervention Type: DRUG; Name: semaglutide; Assigned to Arm(s): Semaglutide 1.0 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Semaglutide placebo 0.5 mg, Semaglutide placebo 1.0 mg

Answer: A